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Abstract
Background: Although neuroimaging techniques have provided insights into the function of brain regions
involved in Trigeminal Neuropathic Pain (TNP) in humans, there is little understanding of the molecular
mechanisms affected during the course of this disorder. Understanding these processes is crucial to determine the
systems involved in the development and persistence of TNP.
Findings: In this study, we examined the regional μ-opioid receptor (μOR) availability in vivo (non-displaceable
binding potential BPND) of TNP patients with positron emission tomography (PET) using the μOR selective
radioligand [11C]carfentanil. Four TNP patients and eight gender and age-matched healthy controls were examined
with PET. Patients with TNP showed reduced μOR BPND in the left nucleus accumbens (NAc), an area known to be
involved in pain modulation and reward/aversive behaviors. In addition, the μOR BPND in the NAc was negatively
correlated with the McGill sensory and total pain ratings in the TNP patients.
Conclusions: Our findings give preliminary evidence that the clinical pain in TNP patients can be related to
alterations in the endogenous μ-opioid system, rather than only to the peripheral pathology. The decreased
availability of μORs found in TNP patients, and its inverse relationship to clinical pain levels, provide insights into
the central mechanisms related to this condition. The results also expand our understanding about the impact of
chronic pain on the limbic system.
Keywords: Trigeminal Neuropathic Pain, Opioid system, Neuroplasticity, Chronic pain, Positron emission
tomography
Introduction
Trigeminal neuropathic pain (TNP) disorders, such as
classical, atypical and postherpetic neuralgias, are persist-
ent pain conditions that can be either spontaneous, or eli-
cited by light touch to the face [1]. The fact that the
current therapeutic modalities that focus only on periph-
eral mechanisms (e.g. microvascular decompression and
percutaneous stereotactic rhizotomy) do not provide long
lasting relief for these frequently treatment-refractory
patients raises the possibility that the causes for the
chronicity of those debilitating disorders may also be
related to central nervous system alterations. In fact, cor-
tical thickness changes were found in TNP patients, which
co-localized with functional (de)activation following allo-
dynic stimulation (brush induced pain) [2]. Furthermore,
those neuroplastic changes in the TNP patients were con-
fined to cortical systems associated with pain experience
and modulation, especially associated with the μ-
opioidergic system, arguably one of the mechanisms cen-
trally involved in the regulation of multiple aspects of the
pain experience [3].
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Studies with positron emission tomography (PET)
using non-selective (e.g., [11C]diprenorphine) radiotra-
cers or [11C]carfentanil, a selective μ-opioid receptor
(μOR) radiotracer, have shown reduced opioid receptor
availability in chronic pain syndromes such as rheuma-
toid arthritis [4], neuropathic pain [5], fibromyalgia [6]
and complex regional pain syndrome [7]. Such findings
might represent either greater occupancy of opioid
receptors by their endogenous ligands, down-regulation
of opioid receptors after persistent activation during
pain, or both [6]. At the present time, it is unknown
whether the μ-opioid system is involved in TNP, and the
clinical consequences of that involvement. A down-
regulation of μORs could explain hypersensitivity (e.g.,
allodynia, comorbidity with other pain disorders) and
frequent treatment refractoriness, including that to opi-
ate medications. Hence, in this preliminary study we
investigated changes in the baseline μORs BPND in
patients diagnosed with TNP when compared to age-
matched pain-free healthy subjects. Based on the exist-
ing literature, we hypothesized that patients suffering
from TNP would show reduced μOR BPND in regions
related to pain regulation, possibly representing persist-
ent activation of the endogenous opioid system and sub-
sequent dysregulation due to the ongoing pain. To our
knowledge, this is the first study investigating changes in




We recruited four right-handed refractory TNP patients
(three males and one female; mean age = 50.5 ± 16.5),
and eight gender and age-matched healthy subjects (six
males and two females, mean age = 44.1 ± 14.9). The se-
lection of TNP patients met the criteria defined by the
International Headache Society (IHS) [8], American
Academy of Orofacial Pain (AAOP) [9] and Inter-
national Association for the Study of Pain (IASP) Ter-
minology [10]. We only included patients with: A) TNP
for at least six months not adequately controlled by pre-
vious medicine therapies; B) Minimal average pain score
of 4 (moderate to severe) in the visual analogue scale
(VAS); C) Unilateral pain; D) Orofacial allodynic region
to mechanical (light touch) or thermal stimulation (heat
or cold) and E) ages from 18 to 65. The exclusion cri-
teria included: A) Evidence of other local pathology (e.g.,
orofacial lesion); B) Recent unrelated orofacial surgery
or trauma (< 6 months); C) History of systemic disorders
(e.g., multiple sclerosis) or D) Chronic pain other than
TNP (e.g., back pain or migraine); E) Use of narcotic
analgesics (< 6 months); F) Major psychiatric illnesses
(current schizophrenia, major depression with suicidal
ideation, or substance abuse within two years); and G)
Contra-indications to PET. All healthy controls were:
right handed; with ages between 18 and 65 years old;
with no history of chronic medical illnesses. Approxi-
mately 43 subjects applied to participate in the TNP
group. However, only four were considered eligible and
completed the study. The reasons that determined the
exclusion of subjects for this group were: age (1), over-
weight (9), presence of other chronic pain disorders (18),
multiple sclerosis (4) and use of opioid medication (7).
Patients in opioid therapy were not recruited for this
study. However, the use of other types of medications
(e.g. analgesics, anticonvulsants and antidepressants) was
not part of the exclusion criteria. This research investi-
gation was carried out in accordance with the bioethical
rules for studies involving human beings of the WMA
(World Medical Association)––Declaration of Helsinki
(1990), and all of the procedures applied were approved
by the University of Michigan Investigational Review
Board for Human Subject Use, and the Radioactive Drug
Research Committee of the US Food and Drug Adminis-
tration. All subjects gave written informed consent prior
to the participation in the study.
Clinical assessment
All subjects were initially screened by obtaining the
medical history, and performing a clinical orofacial pain
exam by a pain specialist. During this visit each subject
was asked to complete the McGill Pain Questionnaire
(MPQ) [11], which provided quantitative measures of
clinical pain. This questionnaire has three major classes
of pain descriptors (sensory, affective and evaluative),
used to measure the subjective pain experience. It also
provides the total Pain Rating Index (PRI), based on the
rank values of the words selected as descriptors and the
Present Pain Intensity (PPI), a 0–5 intensity scale. In
addition to the MPQ, patients with TNP were requested
to complete an craniofacial pain map [12]. Implemented
in an in-house mobile application (PainTrekW, University
of Michigan), this method provides a 3D head and facial
map based on a squared grid system with vertical and
horizontal coordinates using anatomical landmarks.
Each quadrangle, measuring approximately 1.6 cm ×
1.6 cm, frames well-detailed craniofacial and cervical
areas and can be filled by the patient to express his/her
exact pain location. The method allowed the investiga-
tors to precisely localize and measure the total pain area,
as well as the dermatomes involved in each TNP patient
(Figure 1).
Neuroimaging
A T1-weighted anatomical MRI scan was acquired on a 3
Tesla scanner (General Electric, Milwaukee, WI). The MRI
acquisition utilized the following sequence parameters:
axial spoiled-gradient recalled (SPGR) 3D acquisition,
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15.63 bandwidth, repetition time [TR]= 9.2 ms, echo time
[TE]= 1.9 ms, inversion recovery preparation 500 ms, flip
angle = 15°, 25/26 FOV, number of excitations [NEX]= 1,
144 contiguous slices, 1.0 mm slice thickness, 256 x 256
matrix. VBM8 toolbox (http://dbm.neuro.uni-jena.de/
vbm.html) in SPM8 (Wellcome Department of Imaging
Neuroscience Group, London, UK) was used for the
normalization of the MRI data to MNI (Montreal Neuro-
logical Institute) space. PET scans (HR+ scanner; Siemens,
Knoxville, TN) were acquired in 3D mode (reconstructed
full-width/half-maximum resolution 5.5 mm in-plane and
5.0 mm axially), with septa retracted and scatter correc-
tion. Tracer quantity [11C]carfentanil was administered
(10–15 mCi, ≤ 0.03 μg/kg) through an intravenous line
(50% in initial bolus and remainder continuously infused
to more rapidly achieve constant plasma concentrations).
[11C]carfentanil was synthesized at high specific activity
(> 2000 Ci/mmol) by the reaction of [11C]methyliodide
and a non-methyl precursor as previously described
[13,14]. Images were decay-corrected and reconstructed,
and the dynamic frames were coregistered to each other
and transformed into tracer transport (K1 ratio) and
receptor-related (BPND, binding potential) measures. To
avoid the need for arterial blood sampling, these measures
were calculated using a modified Logan graphical analysis
[15], with occipital cortex (a region devoid of μ- opioid
receptors) as the reference region. After 5–7 minutes of
radiotracer administration, the Logan plot becomes lin-
ear with slope =BPND+1, which is proportional to μOR
concentrations (Bmax)/receptor radiotracer affinity (Kd)
(Bmax/KdBPND). PET images were co-registered to the
individual T1-weighted MRI and then normalized by ap-
plying the deformation matrix obtained from the
normalization of the T1-weighted MRI data to μOR bind-
ing maps.
The control subjects and patients with TNP were com-
pared voxel-by-voxel using unpaired t-test on μOR BPND
data. In view of the small sample size of this pilot study,
we set significance at p ≤ 0.001, uncorrected with a priori
hypothesis (regions involved in pain modulation). Clus-
ter size is reported for voxels with p < 0.01 in the area of
statistical significance.
Results
No age differences were found between groups (TNP
and healthy controls, unpaired t-test, t = 0.676, p = 0.86).
TNP patients had average pain duration of 5.4 ± 1.6 years;
two patients presented with either spontaneous or
evoked pain, while the other two presented both pain
modalities. On a scale from 0 to 10 (zero representing
Figure 1 Clinical profile of Trigeminal Neuropathic Pain patients recruited for this study (for more information, refer to the text). The
pain location was accessed by a craniofacial pain map of the face [12]. This method (PainTrekW, University of Michigan) provides a 3D map of
orofacial pain.
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no pain and ten representing worst pain possible) the
average of spontaneous pain intensity (n = 3) was
5.5 ± 1.3, while the average of evoked pain (n = 3) was
5.4 ± 3.9. All TNP patients had previously tried medica-
tions for pain control, including: carbamazepine (subject
TNP 3), oxcarbazepine, gabapentin (subjects TNP1 and
TNP4), pregabalin (subjects TNP 2 and TNP 4) and
amitriptyline (subject TNP 2). Subjects TNP1, TNP2
and TNP3 were under pain control medication during
the study. As described before, patients taking opioids
were not recruited for this study. The Figure 1 sum-
marizes the main clinical characteristics from each TNP
patient included in this study.
TNP patients displayed a significant reduction of the
μOR BPND in the ventral striatal area (z = 2.98, cluster
size 989 mm3, p = 0.001) of the basal ganglia, with the
greatest difference being found in the left nucleus
accumbens (NAc) (peak MNI coordinates x/y/z: -4/4/-
5). (Figure 2A-D).
The correlation analysis between clinical pain levels
and μOR BPND availability in TNP patients showed that
McGill Total PRI scores coincided with reduced μOR in
the left NAc. Reduced μOR BPND in the left NAc was
also associated to higher McGill sensory subscale scores
(Figure 2E).
Discussion
The present study compared the μOR BPND of TNP
patients to age-matched healthy controls. We found a
significant decrease of μOR BPND in the basal ganglia,
located mainly in the left NAc of patients with TNP,
when compared to controls. Other groups have found
reductions in opioid receptor BPND measured with the
non-selective radiotracer [11C]diprenorphine in other
chronic pain disorders, such as rheumatoid arthritis [4],
complex regional pain syndrome [7], cluster headache
[16] and neuropathic pain [5,17,18]. Those changes
involved brain regions known to play important roles in
pain processing, such as the insula, anterior cingulate
cortex, amygdala, hypothalamus, caudate nucleus and
NAc. A significant increase in the volume of distribution
of [11C]diprenorphine (availability of opioid receptors)
was also shown after treatment with radiofrequency
thermocoagulation (RFTC) in patients with trigeminal
pain [19]. Our findings reinforce the concept that the
ongoing pain experience in TNP is linked to the
Figure 2 Changes in the μ-opioid receptor availability in Trigeminal Neuropathic Pain. A-C, Representation of decreased μOR BPND in the
left NAc in axial (A), sagittal (B) and coronal (C) planes (T = 3.2). D, Plots of individual μOR BPND extracted from the left NAc. Each TNP patient is
represented in a black circle and each healthy subject in a white circle. E, Correlations between MPQ scores (PRI and Sensory) and μOR BPND in
the left NAc of TNP patients.
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persistent activation of endogenous opioid neurotrans-
mission and the subsequent downregulation of μ-opioid
receptors. Considering the limited number of patients
recruited for this study, it is possible that increasing the
sample size might expand our results to a broader set of
brain structures.
In our study, the most significant peak in binding po-
tential reduction of μ-opioid receptors was in the left
nucleus accumbens (NAc) of TNP patients when com-
pared to age-matched healthy subjects (Figure 2D). The
NAc is located in the ventral striatum, at the interface of
sensorimotor and limbic systems, and is part of the cir-
cuit involved in the integration of cognitive, affective
and motor responses, which is modulated by the en-
dogenous opioid system [20-22]. It receives inputs from
limbic areas, such as amygdala and prefrontal cortex and
projects to different structures, including brainstem and
ventral pallidum [23]. It is largely recognized to be
involved in reward and aversive behaviors, and in pla-
cebo response [24]. However, there is substantial evi-
dence from both animal [25-27] and clinical studies
[3,24,28] that the NAc is involved in pain processing, in-
cluding TNP [29]. More recently, functional changes in
the NAc signal were observed in a model of peripheral
nerve injury [27], and a decrease in the NAc gray matter
volume was demonstrated in TNP patients [29]. Along
similar line, NAc was the only brain region differentiating
healthy volunteers and chronic low back pain patients in
an fMRI study examining regional brain activations
related to acute painful thermal stimulation [30,31].
Regarding its relationship to the endogenous μ-opioid
system, the NAc was one of the areas where reductions
in μOR BPND were identified in fibromyalgia patients
when compared to healthy controls. Conversely, short-
and long-term increases in the μOR BPND were observed
in the same area after traditional chinese acupuncture,
which were associated with improvements in clinical
pain ratings in fibromyalgia patients [32]. The results of
our study support the evidence of the NAc participation
in the pain processing, previously proposed in the
Motivation-Decision Model of pain [33,34].
Differences in function of NAc μ-opioid receptors
could ultimately contribute to the clinical pain in tri-
geminal neuropathic pain disorders. A negative relation-
ship was detected between the μOR BPND in the left
NAc and the McGill scores (MPQPRI and MPQ sen-
sory) in sample of four TNP patients (Figure 2E). Sub-
jects with higher McGill scores exhibited lower μOR
BPND, and subjects with lower McGill scores displayed
higher μOR BPND. Although the reduced sample size
limits the conclusions about this relationship, the results
suggest a relationship between the clinical presentation
of TNP disorders, and μ-opioid neurotransmission in
the NAc, an area related to both pain processing and
motivational mechanism. Based on our results, it is pos-
sible to hypothesize that the chronicity of trigeminal
neuropathic pain is also related to central nervous sys-
tem molecular neuroplasticity at the level of the μORs in
the limbic area of the basal ganglia. This initial proof of
concept study supports the initiation of further studies
to examine the central molecular mechanisms, such as
endogenous opioid neurotransmission, that may influ-
ence the clinical course and treatment responses of
patients afflicted with persistent TNP.
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